The Annals Summaries of the Latest Medical Research!
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     



Published Online, 18 May 2004, www.theannals.com, DOI 10.1345/aph.1D485.
The Annals of Pharmacotherapy: Vol. 38, No. 7, pp. 1265-1271. DOI 10.1345/aph.1D485
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gentile, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gentile, S.

PSYCHIATRY

Clinical Utilization of Atypical Antipsychotics in Pregnancy and Lactation

Salvatore Gentile, MD

Department of Mental Health, ASL Salerno 1, Head of Mental Health Center District n. 4 Piazza Galdi, 84013 Cava de' Tirreni (SA), Italy, fax 39 089 4455440, salvatore_gentile{at}libero.it

Reprints: Salvatore Gentile MD

OBJECTIVE: To analyze the available literature regarding the safety of atypical antipsychotics in pregnancy and lactation in order to recommend evidence-based strategies for pharmacologic management of psychosis in these conditions.

DATA SOURCES: We summarized the results from articles identified via MEDLINE/PubMed/TOXNET (1993–January 31, 2004), using the key terms pregnancy, lactation, breast-feeding, human milk, psychotropic drugs, atypical antipsychotics, olanzapine, quetiapine, risperidone, clozapine, ziprasidone, and aripiprazole.

STUDY SELECTION AND DATA EXTRACTION: Retrospective studies, clinical observations, and case reports regarding the 6 atypical antipsychotics mentioned above were selected and analyzed. Extensive manual review of pertinent journals and textbooks was also performed.

DATA SYNTHESIS: Reviewed studies show that olanzapine and clozapine apparently do not increase the teratogenic risk if administered to pregnant women, while evidence on quetiapine, risperidone, aripiprazole, and ziprasidone is still limited. In contrast, available information is not able to exclude unwanted serious effects associated with the use of all atypical antipsychotics on mother–infant dyads. Furthermore, more than a few studies suggest increased hyperglycemic risk for pregnant women related to atypical antipsychotic therapy during gestation. Finally, published evidence about the effects on long-term infant neurodevelopment of drug exposure through both placenta and breast milk is represented only by sporadic case reports.

CONCLUSIONS: It is well known that potential consequences of an untreated psychotic episode may be severe and may lead to the mother attempting suicide and/or infanticide. For these reasons, clinicians need to help mothers weigh both fetal and neonatal risks of exposure to drugs against the potential risk they and their infant may incur if the psychiatric illness is not treated. On the other hand, atypical antipsychotics in pregnancy and breast-feeding do not show evident advantages in safety when compared with typical neuroleptic agents. Therefore, we suggest that the most relevant parameters for selecting the best clinical option for pregnant and breast-feeding women with schizophrenia and related disorders remain strongly related to 3 main points: (1) cautious evaluation of the risk/benefit ratio of fetal and neonatal drug exposure, (2) degree of severity of maternal psychiatric illness, and (3) careful preliminary choice of drugs characterized by a balanced safety/efficacy profile.

Key Words: aripiprazole, atypical antipsychotics, breast-feeding, clozapine, olanzapine, pregnancy, quetiapine, risperidone, teratogenic risk, ziprasidone

Published Online, May 18, 2004. www.theannals.com, DOI 10.1345/aph.1D485


This article has been cited by other articles:


Home page
J PsychopharmacolHome page
A. Duran, M. M. Ugur, S. Turan, and M. Emul
Case Report: Clozapine use in two women with schizophrenia during pregnancy
J Psychopharmacol, January 1, 2008; 22(1): 111 - 113.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
M. Rahi, T. Heikkinen, S. Hartter, J. Hakkola, K. Hakala, O. Wallerman, M. Wadelius, C. Wadelius, and K. Laine
Placental transfer of quetiapine in relation to P-glycoprotein activity
J Psychopharmacol, September 1, 2007; 21(7): 751 - 756.
[Abstract] [PDF]


Home page
J. Neuropsychiatry Clin. Neurosi.Home page
D.N. Mendhekar
Possible Delayed Speech Acquisition With Clozapine Therapy During Pregnancy and Lactation
J Neuropsychiatry Clin Neurosci, May 1, 2007; 19(2): 196 - 197.
[Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
D. Mendhekar, J. Sharma, and P. Srilakshmi
Use of Aripiprazole During Late Pregnancy in a Woman with Psychotic Illness
Ann. Pharmacother., March 1, 2006; 40(3): 575 - 575.
[Full Text] [PDF]


Home page
Evid. Based Ment. HealthHome page
S. Gentile
More than half the women with a history of psychosis have a psychiatric episode in the first year after childbirth
Evid. Based Ment. Health, May 1, 2005; 8(2): 33 - 33.
[Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.